Ivabradine for the Therapy of Chronic Stable Angina Pectoris: a Systematic Review and Meta-Analysis.

ABSTRACT:

Background and objectives

Coronary artery disease (CAD) is the number one cause of death worldwide. The I_f channel inhibitor ivabradine serves as second line medication for the CAD leading symptom angina pectoris. This systematic review and meta-analysis assess the existing evidence of ivabradine in angina pectoris.

Methods

We systematically searched MEDLINE, Embase, CENTRAL, and Web of Science (September 2019) for randomized controlled trials (RCTs) that compared ivabradine versus placebo, standard therapy (ST) or other anti-anginal drugs. Two review authors independently assessed trials for inclusion and performed data extraction. We completed a 'risk of bias' assessment for all studies and assessed quality of the trial evidence using the Grading of Recommendati

SUBMITTER: Kalvelage C 

PROVIDER: S-EPMC7440996 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature